30 April 2018
Seventure Partners invests in A-Mansia
A-Mansia Biotech S.A., a belgian microbiome company, announces a €13 million first close of its Series A financing, led by Seventure Partners.
Life Sciences
21 March 2018
Adisseo and Seventure Partners announce €24m First Close of AVF, a New Fund Dedicated to Innovative Animal Health and Nutrition
Seventure Partners, one of Europe’s leaders in financing innovation and a world-leader in Life science microbiome investment, today announces that it has launched AVF, the...
8 March 2018
MaaT Pharma Launches European Clinical Trial in Severe Acute Graft-versus-Host Disease for patients receiving allogeneic Hematopoietic Stem Cell Transplantation
MaaT Pharma, a clinical-stage biopharmaceutical company, received authorization from competent authorities to launch its phase II prospective multicenter clinical trial in...
4 January 2018
Zipongo extends total financing to over $50M to launch FoodScripts™ and lower chronic disease costs
Zipongo plans to use the additional funding to expand its nutrition platform beyond wellness to use food as first-line therapy in treating chronic disease.
7 December 2017
Vedanta Biosciences announces initiation of Phase 1a/1b trial for new drug class of rationally-defined bacteria consortia derived from the human microbiome
VE303 is first known rationally-defined bacterial consortium in powder form to enter the clinic and has recieved Orphan Drug designation from the US FDA for C. difficile...
1 December 2017
Vedanta Biosciences Expands Network of Clinical Collaborations Supporting Development of Microbiome Therapeutics for Cancer Immunotherapy
New collaborations with Leiden University Medical Center and the Mitchell Cancer Institute focused on melanoma and cancers of the bladder, head and neck, and kidneys
13 November 2017
Enhanced understanding of the microbiome is helping medicine via The Economist
Enterome, Eligo Bioscience and Seventure Partners inside !
10 November 2017
Seventure Partners announces the trade sale of its portfolio company Cambrooke Therapeutics, Inc. to Ajinomoto Co. Inc
Seventure Partners, one of Europe’s leaders in financing innovation and a world-leader in the venture investment in the microbiome sector, today announces the trade sale of...
30 October 2017
Enterome’s EB8018, a first-in-class drug candidate targeting Crohn’s disease, successfully completes Phase I study in healthy volunteers
ENTEROME SA, a pioneer of innovative therapies for microbiome-related diseases, is pleased to announce the successful completion of the first Phase 1 clinical study with its...
28 September 2017
LNC THERAPEUTICS raises € 6,5 million and reinforces its R&D in the microbiota field
Cardiometabolic research specialist announces Sandrine Claus appointment as Chief Scientific Officer to lead its microbiota-oriented ambitious strategy.